Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Bristol Myers Squibb Company $BMY

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Bristol Myers Squibb Company (NYSE:BMY) by 6.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,672,259 shares of the biopharmaceutical company’s stock after acquiring an additional 107,540 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.08% of Bristol Myers Squibb worth $77,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in shares of Bristol Myers Squibb during the first quarter worth $2,298,000. Bailard Inc. grew its position in shares of Bristol Myers Squibb by 25.9% in the first quarter. Bailard Inc. now owns 7,160 shares of the biopharmaceutical company’s stock valued at $437,000 after purchasing an additional 1,472 shares in the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of Bristol Myers Squibb by 1.9% during the 1st quarter. Kestra Private Wealth Services LLC now owns 170,104 shares of the biopharmaceutical company’s stock valued at $10,375,000 after purchasing an additional 3,092 shares during the period. Finally, Elyxium Wealth LLC bought a new position in Bristol Myers Squibb in the 1st quarter worth about $256,000. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on BMY shares. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Four analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $54.58.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Stock Up 0.9%

Shares of NYSE BMY traded up $0.44 during midday trading on Monday, hitting $47.09. The stock had a trading volume of 998,331 shares, compared to its average volume of 13,773,452. The business’s 50 day moving average is $45.34 and its 200-day moving average is $46.65. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company has a market cap of $95.86 billion, a P/E ratio of 18.98, a PEG ratio of 2.23 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the prior year, the firm posted $1.80 EPS. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.